Experience

Search Experience
SearchClear


Conducted freedom-to-operate analyses for the commercialization of therapeutic recombinant proteins and monoclonal antibodies for a global specialty pharmaceutical company.

ClientPharmaceutical company
Description
Performed freedom-to-operate analyses to assess the commercialization potential of therapeutic recombinant proteins and monoclonal antibodies for a global specialty pharmaceutical company.
Related People

Our Story

Sutherland Asbill & Brennan LLP is an international law firm helping the Fortune 100, industry leaders, sector innovators and business entrepreneurs solve their biggest challenges and reach their business goals. Dedicated to unfaltering excellence in client service, we are known for our business savvy and industry intelligence, providing creative and custom solutions for each of our clients. Industry and business experience makes the difference for our clients.

click to watch Videocast: DOL Fiduciary Rule Litigation Impacts
Videocast: DOL Fiduciary Rule Litigation Impacts
Atlanta, GA
Washington, DC
© 2017 Sutherland Asbill & Brennan LLP / Sutherland (Europe) LLP
MYBRIEFCASE
Add this page to MYBRIEFCASE
Add Page to MYBRIEFCASE
Experience - Conducted freedom-to-operate analyses for the commercialization of therapeutic recombinant proteins and monoclonal antibodies for a global specialty pharmaceutical company.
Current MYBRIEFCASE Pages
Save ChangesDownload MYBRIEFCASEClear All